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Abstract Apoptosis of vascular smooth muscle cells (SMCs) 
has been described in culture and also during remodelling of the 
artery following injury. However, the mediators that regulate 
apoptosis in SMCs are unknown. Because neurotrophins, a 
family of related polypeptide growth factors, including nerve 
growth factor (NGF) and its cognate receptor TrkA have been 
shown to be strongly expressed in atherosclerotic lesions, the 
present study was undertaken to evaluate in vitro, the activity of 
NGF with regard to apoptosis of confluent cultures of human 
aortic SMCs. We report here that NGF induced apoptosis of 
SMCs in a dose-dependent manner. This effect was detected 
from the concentration of 1 ng/ml and reached a maximum at 
100 ng/ml. The concentration that induced a half-maximum 
effect was 8.8 ng/ml. The pro-apoptotic activity of NGF was time 
dependent and was significant after 3 h of incubation. The pro-
apoptotic activity of NGF was blocked in a dose-dependent 
manner by K-252a, an inhibitor of TrkA tyrosine phosphoryla-
tion, suggesting that a NGF/TrkA signal transduction pathway 
could activate apoptotic cell death programs in human SMCs. 
Significantly, NGF-induced apoptosis was inhibited by wort-
mannin and PD 98059, showing that both PI3 kinase and МБК 
kinase were involved. At a NGF concentration that strongly 
induced apoptosis (100 ng/ml), TGFßl which has been identified 
several times as a protective factor, dose dependently inhibited 
the pro-apoptotic effect of NGF. The IC50 value was 1.5 ng/ml. 
These results indicate that, at least in vitro, TGFßl can inhibit 
the pro-apoptotic activity of NGF for SMCs therefore suggest-
ing that TGFßl has the capacity to diminish the deleterious 
consequences of an excitotoxic or ischemie injury that might 
occur during atherogenesis or following angioplasty. 
© 1997 Federation of European Biochemical Societies. 
Key words: Smooth muscle cell; Apoptosis; NGF; TGFßl 
1. Introduction 
Apoptosis is a physiological non-inflammatory mechanism 
of cell death regulating mass and cyto-architecture of a wide 
variety of tissues. In particular, apoptosis plays an important 
role in embryogenesis, morphogenesis, normal cell turnover 
and hyperplasia [1]. Cell death is also a prominent component 
of the human atherosclerotic plaque with areas of 'necrosis' 
being present in over 80% of primary lesions [2]. Cell death 
has also been detected at all stages of lesion development in 
animal models of atherosclerosis [3,4]. Cell death in the vas-
culature has previously been thought to be due to direct toxic 
insult [5] but recent evidence has indicated that cell death of 
endothelial cells, vascular smooth muscle cells (SMCs) and 
macrophages may occur via a highly regulated process [2,6]. 
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The mechanisms that trigger apoptosis in atherosclerotic le-
sions remain largely unknown but several authors hypothes-
ised that growth factors and cytokines might contribute to 
apoptosis of vascular SMCs during atherogenesis [2,7]. 
Among these mediators, recent studies have suggested that 
nerve growth factor (NGF) plays an important role in regu-
lating the response of vascular SMCs to injury [8]. Indeed, 
increased expression of NGF and its receptor TrkA occurred 
following vascular injury of the rat carotid artery suggesting 
that NGF acts as an autocrine or paracrine mediator during 
SMC hyperplasia [8]. These finding have tended to interpret 
the role of NGF as a trophic factor that promotes innerva-
tion, but the expression of a neurotrophin receptor mRNA in 
vessel mesenchyme of mouse embryos [9] suggested that neu-
rotrophins could be acting directly on SMCs. 
Among the growth factors and cytokines which participa-
tion in the pathogenesis of atherosclerosis has been suggested, 
transforming growth factor ßl (TGFßl) is a potent inhibitor 
of endothelial and SMC proliferation, migration and protease 
secretion [10]. The precise molecular changes that yield these 
activities of TGFßl has been tentatively attributed to a de-
crease of cell-mediated proteolysis and to the subsequent dep-
osition of a new basement membrane and the formation of 
junctional complexes between cells [11]. Moreover, very re-
cently it has been suggested that this protective activities 
might be attributed to the potent inhibitory effect of TGFßl 
with regard to apoptosis [12]. 
In the present study, we have determined the effect of NGF 
on apoptosis of human SMCs and evaluated the effect of 
TGFßl with regard to this process. 
2. Materials and methods 
2.1. Materials 
Human aortic SMCs were purchased from Clonetics (Tebu, Le 
Perray, France). Dulbecco's modified Eagle medium (DMEM) and 
phosphate buffered saline (PBS) were from Gibco-BRL (Cergy-Pon-
toise, France). Fetal calf serum (FCS), penicillin, streptomycin sulfate 
and glutamine were from Boehringer Mannheim (Meylan, Claix, 
France). Human recombinant NGF and wortmannin were obtained 
from Sigma Chemical Co. (L'Isle d'Abeau, France). Human TGFßl 
was from Genzyme S.A. (Cergy Saint Christophe, France). PD 98059 
and K-252a were from Calbiochem (Meudon, France). 
2.2. Cell cultures 
SMCs were routinely cultured in DMEM medium supplemented 
with 10% FCS, 50 U/ml penicillin, 50 μg/ml streptomycin sulfate 
and 4 mM glutamine. Cells were used between the third and 10th 
passage. 
2.3. Measurement of apoptosis 
SMCs were seeded in 35 mm Petri dishes (5xl05 cells/well) in 
DMEM+10% FCS and grown to confluence for 3 days. Culture me-
dium was then aspirated, cells were rinsed and fresh medium+20% 
FCS was added in the presence of saline, TGFßl, NGF, K-252a, 
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wortmannin or PD 98059. Twenty-four hours later, apoptosis was 
measured with a photometric enzyme immunoassay (cell detection 
ELISA, Boehringer Mannheim, Mannheim, Germany) for the quan-
titative detection of cytoplasmic histone-associated DNA fragments 
(mono- and oligonucleosomes). Apoptosis was expressed as mean 
number of oligonucleosomes/105 celisi S.D. Results were from three 
different experiments performed in triplicate. 
3. Results and discussion 
3.1. Pro-apoptotic effect of NGF on human ASMCs 
NGF is the most well-studied representative of neurotro-
phins, a family of trophic factors. NGF has pleiotrophic ef-
fects including the ability to induce differentiation, support 
cell survival, and prevent apoptosis in neuronal progenitor 
cells and immature neurons of the central and peripheral nerv-
ous system [13,14]. However, recent studies have shown that 
NGF induces apoptosis in human medulloblastoma cell lines 
[15] and in neural tumour cells [16]. Two different receptors 
for NGF have been identified including the P75 receptor [17] 
and the TrkA receptor, a transmembrane protein receptor 
with a cytoplasmic tyrosine kinase domain [18]. Recent studies 
have shown that TrkA is of major importance for NGF-medi-
ated signal transduction [18,19]. NGF and its cognate receptor 
the trkA tyrosine kinase have been recently identified in hu-
man and rat vascular SMCs [8]. In these cells, NGF seemed to 
behave as an autocrine or local paracrine mediator of cell 
migration, therefore suggesting that neurotrophins play an 
important role in regulating the response of SMCs to injury. 
On the basis of these various findings, we determined the 
effect of NGF with regard to the apoptosis of human SMCs 
in vitro. In culture, many cell types have been shown to 
undergo apoptosis when deprived of essential growth factors 
[20]. These include vascular endothelial cells deprived of 
bFGF [21], mouse embryo cells after removal of epidermal 
growth factor [22], rat pheochromocytoma PC12 cell line 
and sympatric neurons deprived of NGF [23], hormone-de-
pendent cells of the breast or prostate deprived of steroid [24] 
and glial cells deprived of platelet derived growth factor [25]. 
The present study demonstrates that, on confluent human 
SMCs, removal of FCS resulted after 24 h in a dose-depend-
ent pro-apoptotic effect (Fig. 1). In the presence of 20% FCS 
apoptosis of human SMCs was very low but increased signifi-
cantly when the amount of FCS in the culture medium de-
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Fig. 1. Serum-induced apoptosis of human ASMCs. Confluent 
monolayers of human ASMCs cultured in 35 mm dishes were incu-
bated for 24 h at 37°C in DMEM containing increasing concentra-
tions of FCS. Apoptosis was measured with an ELISA kit as de-
scribed in Section 2 and expressed as mean numbers of 
oligonucleosomes/105 cells ± S.D. (n = 9). 
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Fig. 2. Effect of NGF on apoptosis of human ASMCs. A: Dose-re-
sponse: Confluent monolayers of human ASMCs cultured in 35 mm 
dishes were incubated for 24 h at 37°C in DMEM containing 20% 
FCS and increasing concentrations of NGF. B: Kinetics: Confluent 
monolayers of human ASMCs cultured in 35 mm dishes were incu-
bated for different periods of time at 37°C in DMEM containing 
20% FCS and 100 ng/ml NGF. Apoptosis was measured with an 
ELISA kit as described in Section 2 and expressed as mean numbers 
of oligonucleosomes/105 cells ± S.D. (n = 9). 
creased. After a 24 h incubation in 0.05% FCS, 560 ± 60 oligo/ 
mononucleosomes were detected in 105 SMCs. Under exper-
imental conditions which did not allow the cells to undergo 
apoptosis (i.e. in 20% FCS), NGF induced apoptosis of hu-
man SMCs in a dose-dependent manner (Fig. 2A). This effect 
was detected from the concentration of 1 ng/ml and reached a 
maximum at 100 ng/ml. The concentration that induced a 
half-maximum effect (ED50) was 8.8 ng/ml. The pro-apop-
totic effect of NGF was time dependent (Fig. 2B) and was 
significant after 3 h of incubation. The activity of NGF 
reached a maximum after 24 h of incubation and persisted 
at the same level for at least 7 days. The maximum effect of 
NGF observed was similar to that observed when the cells 
were cultured for 24 h in 0.1% FCS. It is noteworthy that 
this pro-apoptotic activity of NGF occurred without any ef-
fect on cell growth (not shown). 
In order to determine if NGF induced apoptosis of human 
SMCs in a TrkA-dependent manner, we evaluated the activity 
of K-252a, a specific inhibitor of TrkA tyrosine phosphoryla-
tion [15]. K-252a inhibited in a dose-dependent manner the 
pro-apoptotic effect of NGF (100 ng/ml) (Fig. 3). The IC50 
value (concentration which inhibited 50% of the pro-apoptotic 
effect of NGF) was 140 nM. Similar results have been re-
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ported concerning the effect of K-252a with regard to the pro-
apoptotic effect of NGF for human neuroblastoma cell lines 
that express TrkA receptors [15]. 
The mitogen-activated protein kinase (MAP kinase) cascade 
plays a crucial role in the transduction of extracellular signals 
governing cell growth and differentiation. The effects of a 
specific inhibitor of MAP kinase (PD 98059) and of wortman-
nin, a specific inhibitor of phosphoinositide-3' kinase (PI3 
kinase), on NGF-induced apoptosis have also been examined. 
Wortmannin and PD 98059 inhibited in a dose-dependent 
manner the pro-apoptotic effect of NGF for human SMCs 
(Fig. 3). The IC50 values were 7 nM and 40 nM respectively. 
Therefore, as shown previously for other cell types [15,16], 
our studies provide compelling evidence that apoptosis is a 
consequence of the NGF/TrkA signalling pathways. Our re-
sults show that this effect of NGF, through TrkA occurs via 
activation of PI3 kinase and of the MEK/MAP kinase path-
way. Moreover, these results are in agreement with a recent 
study showing that treatment of NIH 3T3 cells expressing the 
TrkA receptor with PD 98059 dramatically reversed the 
growth inhibitory activity of NGF for these cells [26]. 
3.2. Protective effect of TGFfil on NGF-induced apoptosis 
In vitro studies with vascular SMCs have identified several 
growth factors and cytokines that regulate apoptosis. Along 
with platelet derived growth factor-BB and insulin growth 
factor-1, several cytokines such as interferon-γ, tumour ne-
crosis-α and interleukin-lß are now considered to be likely 
candidates [2-4,27,28]. 
Although TGFßl has opposite effects on proliferation ver-
sus migration of SMCs [11,12,29], the precise molecular mech-
anisms for this dual role remain largely undefined but have 
been tentatively attributed to a decrease of cell-mediated pro-
teolysis and the subsequent deposition of new basement mem-
brane and formation of junctional complexes between cells 
[30]. In a recent study, we have shown that TGFßl inhibited 
the pro-apoptotic effect of deprivation of FCS in murine 
SMCs [12]. Furthermore, several studies have shown that 
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Fig. 3. Effect of K-252a, wortmannin or PD 98059 on NGF-induced 
apoptosis of human ASMCs. Confluent monolayers of human 
ASMCs cultured in 35 mm dishes were incubated for 24 h at 37°C 
in DMEM containing 20% FCS, 100 ng/ml NGF and increasing 
doses of K-252a (·), wortmannin (■) or PD 98059 (A) . Apoptosis 
was measured with an ELISA kit as described in Section 2. Data 
are reported as % inhibition of apoptosis compared to cells in 20% 
FCS+100 ng/ml of NGF (n = 9). 
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Fig. 4. Effect of TGFß on NGF-induced apoptosis of human 
ASMCs. A: Dose-response: Confluent monolayers of human 
ASMCs cultured in 35 mm dishes were incubated for 24 h at 37°C 
in DMEM containing 20% FCS, 100 ng/ml NGF and increasing 
doses of TGFß. B: Kinetics: Confluent monolayers of human 
ASMCs cultured in 35 mm dishes were incubated for different peri-
ods of time at 37°C in DMEM containing 20% FCS, 100 ng/ml 
NGF and 100 ng/ml TGFß. Apoptosis was measured with an ELI-
SA kit as described in Section 2. Data are reported as % inhibition 
of apoptosis compared to cells cultured in 20% FCS+100 ng/ml 
NGF (и = 9). 
TGFßl exhibits a protective effect against neuronal degener-
ation caused by different stimuli [31]. In rat hippocampal neu-
rons and in human foetal neurons, this effect seemed to be 
mediated by the ability of TGFßl to increase the expression 
of the anti-apoptotic proteins Bcl-2 and Bcl-xL [32]. 
In the present study, we showed that, when added to hu-
man SMCs, TGFßl inhibited in a dose-dependent manner the 
pro-apoptotic effect of NGF (Fig. 4A). This activity was sig-
nificant from the dose of 10 pg/ml and reached a maximum at 
100 ng/ml. The IC50 value was 1.5 ng/ml. This inhibition of 
the pro-apoptotic activity of NGF was time dependent (Fig. 
4B). The inhibitory activity of TGFßl was significant after 3 h 
and reached a maximum after 14 h of incubation with the 
cells. As shown by us previously [12], a similar effect was 
observed with regard to FCS depletion-induced apoptosis 
(not shown). 
The mechanism(s) responsible for the potent anti-apoptotic 
activity of TGFßl remain largely unknown but can be com-
pared with the protective effect of TGFßl observed on cul-
tured hypocampal neurons, cardiac myocytes or endothelial 
cells [33]. In these experiments, TGFßl was shown to protect 
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these cells against a wide range of toxic insults (death induced 
by excitotoxicity, trophic factor removal or oxidative injury) 
by regulating two factors with great importance for cell via-
bility: i.e. acute stabilisation of calcium homeostasis under 
conditions of physiological calcium overload but also via rap-
id induction of the Bcl2 oncoprotein [32,33]. Alternatively, 
TGFßl may have indirect effects via induction of other neuro-
trophic agents such as bFGF [34] or insulin like growth factor 
[35]. TGFßl has also been demonstrated to reduce the release 
of TNFa [36], a cytokine which strong pro-apoptotic activity 
for SMCs has been shown several times [37]. Thus, although 
not directly examined in the present study, it is conceivable 
that such mechanisms alone or in synergy might be respon-
sible for the strong inhibitory activity of TGFßl observed 
with regard to the pro-apoptotic effect of NGF for SMCs. 
In conclusion, our work shows for the first time that the 
activity of NGF as a trophic factor for vascular SMCs might 
be attributed to its potent pro-apoptotic effect. The NGF/ 
TrkA pathway was involved in this activity through an acti-
vation of PI3 kinase and the (MEK)/MAP kinase pathway. 
TGFßl was a potent inhibitor of the pro-apoptotic effect of 
NGF suggesting that it might be an essential factor in the 
regulation of apoptosis of SMCs which occur following vas-
cular injury or during atherogenesis. 
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